Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management

Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management

Targeted anticancer therapies, unlike the traditional cytotoxic chemotherapies which lead to systemic toxicities, frequently cause cutaneous adverse events that are symptomatic and manifest in cosmetically sensitive areas. The most common dermatologic toxicities related to epidermal growth factor re...

Full description

Bibliographic Details
Main Authors:	Pei-Han Kao, Jen-Shi Chen, Wen-Hung Chung, Rosaline Chung-Yee Hui, Chih-Hsun Yang
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-12-01
Series:	Journal of Cancer Research and Practice
Subjects:	targeted therapy dermatologic toxicities epidermal growth factor receptor tyrosine kinase inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2311300616300866

Similar Items

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01)

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
by: Chia-Yu Chu, et al.
Published: (2017-06-01)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Katsuhiro Masago, et al.
Published: (2018-01-01)

Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
by: Philomena Charlotte Dsouza, et al.
Published: (2017-01-01)

Targeted therapy: A novel approach in head and neck cancer
by: A Winnifred Christy, et al.
Published: (2013-01-01)

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
by: Chen CB, et al.
Published: (2018-05-01)

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
by: Witold Owczarek, et al.
Published: (2017-10-01)

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study
by: Barbu Maria Alexandra, et al.
Published: (2018-06-01)

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
by: Gerendash BS, et al.
Published: (2017-10-01)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
by: Mohammad Hojjat-Farsangi
Published: (2014-08-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
by: Rania S.M. Ismail, et al.
Published: (2016-06-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
by: Santa Cirmi, et al.
Published: (2020-03-01)

Immunopathogenetic mechanisms of skin toxic response of antitumor therapy with mul-tikinase of angiogenesis inhibitors
by: Shatokhina Е.А., et al.
Published: (2017-09-01)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
by: Massimo Santoro, et al.
Published: (2020-04-01)

Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
by: Michael Dörks, et al.
Published: (2021-02-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
by: Xiaoyan Si, et al.
Published: (2019-03-01)

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms
by: Monika Lejman, et al.
Published: (2021-09-01)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
by: Andrea Francis, BS, et al.
Published: (2021-01-01)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
by: Sangtian Liu, et al.
Published: (2021-03-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
by: Liling Huang, et al.
Published: (2020-10-01)

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies
by: Li GZ, et al.
Published: (2019-07-01)

NTRK fusions in osteosarcoma are rare and non‐functional events
by: Baptiste Ameline, et al.
Published: (2020-04-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01)

A rare case of late presentation of dasatinib-induced cardiopulmonary toxicity
by: Harshit Khurana, et al.
Published: (2021-01-01)

Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway
by: Rosalinda Madonna, et al.
Published: (2020-03-01)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
by: Chaar M, et al.
Published: (2018-09-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations
by: Wenxing DU, et al.
Published: (2019-09-01)

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
by: German G. Gomez, et al.
Published: (2013-12-01)

Advances in Antiangiogenic Treatment of Advanced Non-squamous Non-small Cell Lung Cancer in 2017 ASCO and WCLC
by: Lianfang NI, et al.
Published: (2018-05-01)